COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,761 Articles (22,502 medRxiv, 8,259 bioRxiv)

Most recent first Previous |  Page 3014: Articles 30131-30140  | Next

Transmissibility of 2019 Novel Coronavirus: zoonotic vs. human to human transmission, China, 2019-2020
Mizumoto, K., Kagaya, K., Chowell, G.
10.1101/2020.03.16.20037036 — Posted: 2020-03-20
Analysis of Epidemic Situation of New Coronavirus Infection at Home and Abroad Based on Rescaled Range (R/S) Method
Ji, X., Tang, Z., Wang, K., Li, X., Li, H.
10.1101/2020.03.15.20036756 — Posted: 2020-03-20
GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY
Zehender, G., Lai, A., Bergna, A., Meroni, L., Riva, A., Balotta, C., Tarkowski, M., Gabrieli, A., Bernacchia, D., Rusconi, S., Rizzardini, G., Antinori, S., Galli, M.
10.1101/2020.03.15.20032870 — Posted: 2020-03-20
Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2
Liu, W., Liu, L., Kou, G., Zheng, Y., Ding, Y., Ni, W., Wang, Q., Tan, L., Wu, W., Tang, S., Xiong, Z., Zheng, S.
10.1101/2020.03.16.20035014 — Posted: 2020-03-20
Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase
Chien, M., Anderson, T. K., Jockusch, S., Tao, C., Kumar, S., Li, X., Russo, J. J., Kirchdoerfer, R., Ju, J.
10.1101/2020.03.18.997585 — Posted: 2020-03-20
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., Kim, S.
10.1101/2020.03.20.999730 — Posted: 2020-03-20 Discussion: Onsite
Scientometric Trends for Coronaviruses and Other Emerging Viral Infections
Kagan, D., Moran-Gilad, J., Fire, M.
10.1101/2020.03.17.995795 — Posted: 2020-03-20
Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning
Magar, R., Yadav, P., Barati Farimani, A.
10.1101/2020.03.14.992156 — Posted: 2020-03-20
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
Sheahan, T. P., Sims, A. C., Zhou, S., Hill, C., Leist, S. R., Schaefer, A., Agostini, M., Pruijssers, A., Brown, A. J., Bluemling, G., Natchus, M., Saindane, M., Kolykhalov, A., Painter, G., Swanstrom, R., Dinnon, K., Graham, R., Harcourt, J., Tamin, A., Thornburg, N. J., Montgomery, S. A., Chappell, J., Denison, M., Baric, R. S.
10.1101/2020.03.19.997890 — Posted: 2020-03-20 Discussion: Onsite
The first-in-class peptide binder to the SARS-CoV-2 spike protein
Zhang, G., Pomplun, S., Loftis, A. R., Loas, A., Pentelute, B. L.
10.1101/2020.03.19.999318 — Posted: 2020-03-20 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).